Holen Sie sich die Stockscreener-App
0.8736
8.24%
-0.0784
Handel nachbörslich:
.87
-0.0036
-0.41%
Schlusskurs vom Vortag:
$0.952
Offen:
$0.938
24-Stunden-Volumen:
328.57K
Relative Volume:
0.62
Marktkapitalisierung:
$209.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.24B
KGV:
0.0343
EPS:
25.475
Netto-Cashflow:
$-31.80M
1W Leistung:
-2.93%
1M Leistung:
-23.37%
6M Leistung:
-23.70%
1J Leistung:
-1.62%
1-Tages-Spanne:
$0.8529
$0.938
1-Wochen-Bereich:
$0.8529
$1.06
52-Wochen-Spanne:
$0.66
$2.10
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
0.8736 | 227.83M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-02 | Bestätigt | H.C. Wainwright | Buy |
Enlivex Ltd Aktie (ENLV) Neueste Nachrichten
ENLV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ENLV PE Ratio & Valuation, Is ENLV Overvalued - Intellectia AI
Enlivex clears pivotal FDA hurdle in knee osteoarthritis - Longevity.Technology
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
Market Wrap: What analysts say about Enlivex Therapeutics Ltd stock2026 Big Picture & Technical Entry and Exit Tips - baoquankhu1.vn
Enlivex shares jump after earnings as treasury gains boost results - MSN
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Enlivex Announces $21M Debt Financing and Prediction Markets Treasury Expansion - Bitcoin.com News
RAIN Token Climbs to 25th in Market Cap Following Institutional Activity and Protocol Upgrades - Bitget
Enlivex Therapeutics Tokenized Stock (Ondo) price today, ENLVon to USD live price, marketcap and chart - CoinMarketCap
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 - NewMediaWire
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 | Corporate - EQS News
Published on: 2026-03-26 22:45:56 - baoquankhu1.vn
Enlivex Reports Full-Year 2025 Results, Profit of $1.23 Billion and Diluted Earnings per Share of $25.48 - marketscreener.com
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains - The Globe and Mail
Enlivex Highlights Rain’s AI Agent Launch and $5 Million Grant Program to Expand Prediction Markets - tipranks.com
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt - manilatimes.net
Enlivex (NASDAQ: ENLV) highlights Rain AI launch, $5M grants and RAIN token burn - Stock Titan
One prompt can now create a live prediction market as Rain adds $5M - Stock Titan
Enlivex Obtains $21 Million Loan to Purchase RAIN Tokens and Initiate $20 Million Buyback - Bitget
Earnings call transcript: Enlivex Q4 2025 sees stock surge on treasury gains - au.investing.com
Envilex Therapeutics (ENLV) Reports Strong FY GAAP EPS - GuruFocus
Enlivex Soars After FDA Approval for Allocetra Trial - StocksToTrade
Enlivex Stock Boosted by FDA Approval for Allocetra in Osteoarthritis Trials - timothysykes.com
Enlivex Therapeutics Q4 Earnings Call Highlights - marketbeat.com
Enlivex Allocetra Takes A Leap as FDA Clears Phase 2b Trial for Osteoarthritis - timothysykes.com
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 - Bitget
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback - The Globe and Mail
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS - MarketBeat
Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation - Quiver Quantitative
Biotech–crypto hybrid Enlivex (NASDAQ: ENLV) outlines RAIN treasury risks and funding needs - Stock Titan
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted ... - Bluefield Daily Telegraph
Enlivex (NASDAQ: ENLV) nets $1.23B in 2025 on digital treasury gains - Stock Titan
Treasury gains push Enlivex to $1.23B profit, $2.31B in assets - Stock Titan
Enlivex secures $21M debt financing, buys more RAIN tokens By Investing.com - Investing.com Australia
Strategic Move: Enlivex Allocates $21 Million for RAIN Token Acquisition Amid Share Buyback - MEXC
Enlivex Raises $21 Million to Expand RAIN Token Treasury Holdings - Blockonomi
Enlivex Raises $21M to Expand RAIN Token Treasury and Biotechnology Pipeline - MoneyCheck
Enlivex Secures $21M Funding to Boost RAIN Treasury Strategy - CoinCentral
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Enlivex stock rating held at Hold by D. Boral Capital after debt deal - Investing.com Australia
Enlivex Funding Rounds, Token Sale Review & Tokenomics Analysis - CryptoRank
Enlivex secures $21M debt financing, buys more RAIN tokens - Investing.com
Finanzdaten der Enlivex Ltd-Aktie (ENLV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):